Coherus Oncology, Inc. (CHRS)
CHRS moved a median of +0.21% 30 minutes after news, and -1.38% by the close. How CHRS actually reacts to news — the realized, point-in-time move the market made, measured across 276 labeled events over the last three years with zero look-ahead.
CHRS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 276 |
| 30-min | +0.21% | 51% | 276 |
| 60-min | -0.29% | 45% | 276 |
| to close | -1.38% | 38% | 276 |
| Middle 50% of CHRS reactions | -1.90% to +1.94% |
|---|---|
| Median reaction (30-min) | +0.21% |
| Measured reactions | 276 |
Half of all Coherus Oncology, Inc. news events land between -1.90% and +1.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CHRS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | -0.76% | 25% | -1.50% |
| Analyst downgrades | 13 | -1.71% | 23% | -10.18% |
| Coverage initiations | 10 | +1.06% | 100% | +11.35% |
| Rating reiterations | 42 | +0.56% | 52% | -0.50% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CHRS ranks against every other measured name →
That’s how CHRS usually reacts — get an email when it moves on news →Email me when CHRS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CHRS's baseline. Nothing else.
Recent CHRS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 | Press release | GlobeNewswire | +0.47% | +0.00% | |
| Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets | Press release | GlobeNewswire | -1.15% | -3.82% | |
| Coherus to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.72% | -2.88% | |
| Form 8-K Coherus Oncology, Inc. For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -2.88% | |
| Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | Press release | GlobeNewswire | -0.40% | +6.35% | |
| Form 8-K Coherus Oncology, Inc. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +6.35% | |
| Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +3.99% | -8.33% | |
| Form 10-Q Coherus Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.99% | -8.33% | |
| Form 8-K Coherus Oncology, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +3.99% | -8.33% | |
| Form S-8 Coherus Oncology, Inc. | SEC filing · Form S-8 | SEC EDGAR | +3.99% | -8.33% | |
| Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | GlobeNewswire | +0.00% | -0.35% | |
| Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) | Press release | GlobeNewswire | +1.69% | -1.35% | |
| Form 8-K Coherus Oncology, Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | +0.73% | |
| Form 8-K Coherus Oncology, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | -1.88% | |
| Form DEFA14A Coherus Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.58% | +0.00% | |
| Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.51% | -2.29% | |
| Form 10-Q Coherus Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.51% | -2.29% | |
| Form 8-K Coherus Oncology, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | -2.29% | |
| Form DEFA14A Coherus Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.10% | -3.31% | |
| Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 | Press release | GlobeNewswire | +1.40% | -2.81% | |
| Form ARS Coherus Oncology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.26% | +1.53% | |
| Form DEF 14A Coherus Oncology, Inc. For: May 27 | SEC filing · Form DEF | SEC EDGAR | +0.26% | +1.53% | |
| Form DEFA14A Coherus Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.84% | +5.03% | |
| Form PRE 14A Coherus Oncology, Inc. For: May 27 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +2.44% | |
| Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.54% | +4.84% | |
| Form 10-K Coherus Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.54% | +4.84% | |
| Form 8-K Coherus Oncology, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | +4.84% | |
| Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 | Press release | GlobeNewswire | +1.88% | +3.13% | |
| Coherus Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.02% | -0.59% | |
| Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock | Press release | GlobeNewswire | -1.24% | +0.62% | |
| Form 8-K Coherus Oncology, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +0.62% | |
| Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | +2.35% | -5.29% | |
| Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | +2.35% | -5.29% | |
| Form 8-K Coherus Oncology, Inc. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +5.04% | -2.63% | |
| Form 8-K Coherus Oncology, Inc. For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +3.91% | +12.87% | |
| Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape | Press release | PR Newswire | -2.40% | -4.19% | |
| Form 8-K Coherus Oncology, Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +2.41% | |
| Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.34% | -6.85% | |
| SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer | Press release | GlobeNewswire | -1.02% | -7.48% | |
| Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) | Press release | GlobeNewswire | +1.45% | +3.60% | |
| Form EFFECT Coherus Oncology, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.15% | -0.77% | |
| Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma | Press release | GlobeNewswire | +5.29% | +4.07% | |
| Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody | Press release | GlobeNewswire | -0.74% | -0.74% | |
| Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | Press release | GlobeNewswire | +1.01% | +0.34% | |
| Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.74% | -0.74% | |
| Form 10-Q Coherus Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.74% | -0.74% | |
| Form 8-K Coherus Oncology, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | -0.74% | |
| Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | GlobeNewswire | -1.16% | -1.73% | |
| Coherus Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -1.18% | |
| Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | Press release | GlobeNewswire | +0.60% | -1.80% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CHRS section they belong to.
Where else CHRS is measured.
CHRS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) | 278 | -0.48% | 36% |
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Xenon Pharmaceuticals Inc. - Common Shares (XENE) | 276 | +0.03% | 50% |
| Aclaris Therapeutics, Inc. (ACRS) | 275 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Coherus Oncology, Inc.'s median reaction calculated?
Every labeled CHRS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 276 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of CHRS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CHRS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.